PAPER Nerelius C, Johansson J, Sandegren A

Amyloid beta-peptide aggregation. What does it result in and how can it be prevented?

Front Biosci. 2009;14:1716-29. PubMed: 19273157

PAPER Sohn JH, So JO, Hong HJ, Kim JW, Na DR, Kim M, Kim H, Nam E, Ha HJ, Kim YH, Mook-Jung I

Identification of autoantibody against beta-amyloid peptide in the serum of elderly.

Front Biosci. 2009;14:3879-83. PubMed: 19273318

PAPER Love S, Miners S, Palmer J, Chalmers K, Kehoe P

Insights into the pathogenesis and pathogenicity of cerebral amyloid angiopathy.

Front Biosci. 2009;14:4778-92. PubMed: 19273389

PAPER Mecocci P, Bladström A, Stender K

Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.

Int J Geriatr Psychiatry. 2009 May;24(5):532-8. PubMed: 19274640

PAPER Maheswaran S, Barjat H, Rueckert D, Bate ST, Howlett DR, Tilling L, Smart SC, Pohlmann A, Richardson JC, Hartkens T, Hill DL, Upton N, Hajnal JV, James MF

Longitudinal regional brain volume changes quantified in normal aging and Alzheimer's APP x PS1 mice using MRI.

Brain Res. 2009 May 13;1270:19-32. PubMed: 19272356

PAPER Craft S

The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged.

Arch Neurol. 2009 Mar;66(3):300-5. PubMed: 19273747

PAPER Fitzpatrick AL, Kuller LH, Lopez OL, Diehr P, O'Meara ES, Longstreth WT, Luchsinger JA

Midlife and late-life obesity and the risk of dementia: cardiovascular health study.

Arch Neurol. 2009 Mar;66(3):336-42. PubMed: 19273752

PAPER Helzner EP, Luchsinger JA, Scarmeas N, Cosentino S, Brickman AM, Glymour MM, Stern Y

Contribution of vascular risk factors to the progression in Alzheimer disease.

Arch Neurol. 2009 Mar;66(3):343-8. PubMed: 19273753

PAPER Qin W, Haroutunian V, Katsel P, Cardozo CP, Ho L, Buxbaum JD, Pasinetti GM

PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia.

Arch Neurol. 2009 Mar;66(3):352-61. PubMed: 19273754

PAPER Brar S, Henderson D, Schenck J, Zimmerman EA

Iron accumulation in the substantia nigra of patients with Alzheimer disease and parkinsonism.

Arch Neurol. 2009 Mar;66(3):371-4. PubMed: 19273756

PAPER Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T

Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.

Arch Neurol. 2009 Mar;66(3):382-9. PubMed: 19273758

PAPER Bracco L, Giovannelli F, Bessi V, Borgheresi A, Di Tullio A, Sorbi S, Zaccara G, Cincotta M

Mild cognitive impairment: loss of linguistic task-induced changes in motor cortex excitability.

Neurology. 2009 Mar 10;72(10):928-34. PubMed: 19273828

VEGFR-1 /Flt-1 (H-225)

ANTIBODY polyclonal manufacturer Cat# sc-9029 immnuogen = amino acids 23-247 mapping within the extracellular domain of Flt-1 of human origin liquid IgG, PBS, azide, gelatin detects Flt-1, 180 kDa IgG Growth Factors Santa Cruz Rabbit Human Mouse Rat VEGFR-1 /Flt-1

VEGFR-1 /Flt-1 (Rt-19)

ANTIBODY monoclonal Rt-19 manufacturer Cat# sc-65442 immnuogen = Flt-1 of human origin liquid, PBS, azide, gelatin detects Flt-1 IgG Growth Factors Santa Cruz Mouse Human VEGFR-1 /Flt-1 http://alzforum.org/res/com/ant/default.asp?antibodyID=30607

VEGFR-1 /Flt-1 (EWF)

ANTIBODY monoclonal EWF manufacturer Cat# sc-57139 immnuogen = extracellular domain of Flt-1 of human origin liquid, PBS, azide, gelatin detects recombinant and native Flt-1 IgG₁ Growth Factors Santa Cruz Mouse Human VEGFR-1 /Flt-1 http://al